# Article information:

Targeting TREM2 on tumor-associated macrophages enhances immunotherapy: Cell Reports
[https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01308-5?\_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124721013085%3Fshowall%3Dtrue](https://www.cell.com/cell-reports/fulltext/S2211-1247%2821%2901308-5?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124721013085%3Fshowall%3Dtrue)

# Article summary:

1. TREM2+ tumor-associated macrophages (TAMs) are associated with T cell exhaustion and anti-PD-1 resistance.

2. Anti-TREM2 monoclonal antibody therapy promotes anti-tumor immunity by eliminating and modulating TAM populations, leading to enhanced CD8+ TIL infiltration and effector function.

3. Anti-TREM2 therapy has the potential to potentiate T cell activation and response to anti-PD-1 treatment in individuals who are refractory to CPI therapy.

# Article rating:

Appears well balanced: The article presents the information in a reliable and balanced way, without biases and prejudices. The claims made in the article are well supported and, where applicable, all sides of the argument are given opportunity to present their point of view. The article appears trustworthy and reliable.

# Article analysis:

The article is generally reliable and trustworthy, as it provides evidence for its claims through research studies conducted on mouse syngeneic tumor models, human solid tumors of multiple histological types, and an aggressive orthotopic ovarian cancer model. The article also cites relevant literature to support its claims, such as Jenkins et al., 2018; Le et al., 2017; Miller et al., 2019; Pauken et al., 2016; Philip et al., 2017; Dammeijer et al., 2017; Dannenmann et al., 2013; Jahchan et al., 2019; DeNardo and Ruffell, 2019; Lewis and Pollard, 2006; Peranzoni et al., 2018; Viitala et al., 2019. The article does not appear to be biased or one-sided in its reporting, as it presents both sides of the argument equally. It also does not appear to contain any promotional content or partiality towards any particular viewpoint or opinion. Furthermore, the article does not appear to be missing any points of consideration or evidence for the claims made, nor does it contain any unexplored counterarguments or missing evidence for the claims made. Finally, the article does note possible risks associated with anti-TREM2 therapy such as potential side effects that may arise from targeting TAMs in individuals who are refractory to CPI therapy. In conclusion, this article is generally reliable and trustworthy in its reporting of research findings related to targeting TREM2 on TAMs for immunotherapy purposes.

# Topics for further research:

* TREM2 immunotherapy side effects
* TAMs and cancer immunotherapy
* TREM2 and cancer treatment
* Syngeneic tumor models
* CPI therapy and TREM2
* TREM2 and TAMs in cancer immunotherapy

# Report location:

<https://www.fullpicture.app/item/7d1238aa72b649957dd9ad56d371c30f>